Section 4 of 6
Clinical evidence
192 evidence topics · 48 sources
Study summaries
Pooled phase I/II analysis versus external control
Objective
Pooled analysis protocols and prespecified external control comparison, September 2025
Comparison of Cohorts 1 and 2 with an Enroll-HD external control as the basis for a BLA
Updated external control comparison in the pooled protocols, September 2026
Location and study date
Data cutoff of the three-year analysis
Data cutoff of the four-year and updated 36-month analyses
Enroll-HD dataset releases used as external controls
Clinical trial sites of CT-AMT-130-01 and CT-AMT-130-02
Data cutoff of the 24-month interim analysis, July 2024
Data cutoff of the interim analysis, December 2023
Study design
Prespecified statistical analysis plan of the three-year analysis
Propensity score-matched external control reported as the prespecified primary comparison, September 2025
Statistical analysis plan as described in June 2025: propensity score-weighted primary analysis planned
Rationale for selecting Enroll-HD
Propensity score matching method and covariates
Statistical analysis plan of the 48-month analysis with an updated external control
Propensity-weighted TRACK-HD, TRACK-ON, and PREDICT-HD external control, July 2024
Criteria-matched TRACK-HD natural history cohort, December 2023
Eligibility criteria
Key eligibility criteria of the high-dose cohort in the three-year analysis
“Aged 25-65 years” (opens the source at this quote in a new tab)
“Diagnostic confidence level: 3 or 4” (opens the source at this quote in a new tab)
“Total functional capacity: 9-13” (opens the source at this quote in a new tab)
“HD medications stable prior 3 months” (opens the source at this quote in a new tab)
“Striatal volumes exceed specified minima” (opens the source at this quote in a new tab)
“Putamen: ≥ 2.5 cm3/side” (opens the source at this quote in a new tab)
“Caudate: ≥ 2.0 cm3/side” (opens the source at this quote in a new tab)
Selection of the Enroll-HD external control: exclusion criteria
Treatment
Treated participants by dose and imitation surgery controls, July 2024
Study outcomes
Rationale for using cUHDRS change at 36 months as the primary endpoint
Primary, secondary, and supportive endpoints of the three-year analysis
Primary endpoint of the 48-month analysis
Components of the cUHDRS as described by the sponsor
| Component | Domain described |
|---|---|
| Total Functional Capacity (TFC) | “Impairments in occupation, finance, domestic chores, daily living, and care level” |
| Total Motor Score (TMS) | “Impairment in motor function” |
| Symbol Digit Modalities Test (SDMT) | “Measure of attention, processing speed, and working memory” |
| Stroop Word Reading Test (SWRT) | “Measure of selective attention capacity and processing speed” |
Regulatory acceptance of cUHDRS as an intermediate clinical endpoint, December 2024
Sponsor statement on the sensitivity of the cUHDRS
Derivation of the cUHDRS from four UHDRS measures
“The overall pattern of the correlations and the PCA results indicated that TMS, TFC, SDMT, and SWR had significant overlap, but PBA-apathy did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note the negative sign for (scaled) TMS and the positive sign for all other variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed difference in the S/N ratio between the cUHDRS and each individual component in TRACK-HD was numerically superior in all cases (e.g., 26%–38% larger than the best individual measure, which was the TMS at 24 and 36 months, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The results (ICC2,1 = 0.96)9 showed excellent test-retest reliability of the cUHDRS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinically efficacious slowing on the cUHDRS
“We have reached consensus that a slowing of clinical decline in the range of 20% to 30% annually on the cUHDRS (≈0.2–0.3 points per year), equivalent to ≈2.4 to 3.5 mo/y of time saved from progression, can be used to define a clinically efficacious treatment in this setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Correlation of the cUHDRS with imaging biomarkers
“Worse performance in the cUHDRS over time correlated with longitudinal volume decreases in the occipito-parietal cortex and centrum semiovale, whereas lower baseline scores correlated with decreased volume in the basal ganglia and surrounding WM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cUHDRS correlates with imaging biomarkers and tracks atrophy progression in HD supporting its biological relevance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: Total Functional Capacity
“It assesses capacity as opposed to actual performance and consists of a 5‐item interview between a clinician, and the patient and a person familiar with the patient's functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extensive data from multiple observational studies and clinical trials suggest sensitivity to change over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There appears to be a ceiling effect for early stage HD and a floor effect for late stage HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation: The UHDRS‐TFC is suggested for assessing severity of limitation in functional capacity in HD, because it lacks core clinimetric data, namely, test–retest reliability and internal consistency to reach a “recommended” status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Total Functional Capacity as a measure of daily function: investigator statement
Secondary endpoints: Symbol Digit Modalities Test and Stroop Word Reading Test
“(1) the symbol digit modalities test (SDMT/sampled cognitive domains: visual attention, working memory, symbolic encoding, and psychomotor speed), in which the total score corresponds to the number of correct responses within 90 seconds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(2) the Stroop color word interference test (sampled cognitive domains: psychomotor speed, cognitive flexibility, response inhibition, and selective attention), which includes 3 conditions (word reading, color naming, interference), each one of which is scored as the total number of items accurately completed within 45 seconds” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Supportive endpoint: cerebrospinal fluid neurofilament light chain
Natural history of cerebrospinal fluid neurofilament light chain in the HD-CSF cohort
“mHTT in CSF, as well as NfL in CSF and plasma, all rose detectably within participants over 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of simulations of the models in Fig. 2 (D to F), CSF NfL rose in manifest HD by 98.85 pg/ml per year, in preHD by 79.16 pg/ml per year, and in controls by 20.05 pg/ml per year (Fig. 2J).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history comparator for cerebrospinal fluid neurofilament light chain, July 2024
Statistical analysis description
Number of participants (Planned and analyzed)
Participants and external controls in the three-year analysis
Participants and external controls in the four-year and updated 36-month analyses
Participants with data at each visit in the four-year analysis, high dose
| Group and endpoint | Baseline | 12 months | 24 months | 36 months | 48 months |
|---|---|---|---|---|---|
| AMT-130 high dose (cUHDRS and TFC) | “17” | “17” | “15” | “15” | “12” |
| Enroll-HD B, cUHDRS | “1337” | “953” | “760” | “690” | “625” |
| Enroll-HD B, TFC | “1337” | “967” | “772” | “704” | “641” |
| Enroll-HD A, cUHDRS (post hoc) | “619” | “484” | “398” | “355” | “349” |
| Enroll-HD A, TFC (post hoc) | “619” | “492” | “401” | “360” | “364” |
Participants in the 24-month interim analysis, July 2024
Participants in the interim analysis, December 2023
Description of analysis sets
Derivation of the Enroll-HD external control arm analysis set
| Step | Participants |
|---|---|
| Diagnosis of HD in ENROLL-HD | “N = 19,542” |
| Met AMT-130 eligibility criteria | “N = 6,596 (33.8%)” |
| Did not meet AMT-130 eligibility criteria | “N = 12,946” |
| Excluded from the analysis set | “N = 3,326” |
| External control arm analysis set | “N = 3,270 (49.6%)” |
| Propensity-score matched to High-Dose cohort | “N = 940” |
Analysis method for the primary and key secondary endpoints
Primary and post hoc comparisons in the 48-month analysis
Safety analysis set and adverse event definitions, June 2025 data cutoff
Results
Participant disposition
Lumbar puncture declined at 36 months
Baseline characteristics
Demographic and baseline characteristics of the high-dose cohort and the propensity score-matched external control
| Characteristic, mean (SD) | AMT-130 high dose (N=17) | PSM external control, Enroll-HD (N=940) |
|---|---|---|
| Sex, males (%) | “47.1” | “55.6” |
| Age | “45.8” | “45.2” |
| CAG repeats | “42.4” | “42.8” |
| CAP100 score | “86.2” | “86.8” |
| DCL = 3, 4 (%) | “35.3, 64.7” | “30.5, 69.5” |
| PIN score | “0.77” | “0.81” |
| cUHDRS | “14.9” | “14.7” |
| TFC | “12.2” | “12.1” |
| SDMT | “46.1” | “45.3” |
| SWRT | “89.9” | “87.6” |
| TMS | “12.1” | “11.6” |
| HD-ISS Stage 2, 3 (%) | “47.1, 52.9” | “51.6, 48.4” |
| Region; No. America, Other (%) | “58.8, 41.2” | “28.9, 71.1” |
Baseline scores of the treated cohorts, December 2023
Efficacy results
Primary endpoint at 36 months: cUHDRS, high dose
Key secondary endpoint at 36 months: TFC, high dose
Other secondary endpoints at 36 months: SDMT, high dose
Other secondary endpoints at 36 months: SWRT and TMS, high dose
Results at 36 months, low dose
| Endpoint | AMT-130 low dose (N=12), LSM change (SE) | Enroll-HD PSM external control, LSM change (SE) | External control N | LSM difference [95% CI] | Slowing of disease progression (%) | P-value |
|---|---|---|---|---|---|---|
| cUHDRS | “-1.65 (0.411)” | “-1.72 (0.151)” | “N=383” | “0.07 [-0.75, 0.88]” | “3.9” | “0.871” |
| TFC | “-0.33 (0.296)” | “-1.04 (0.120)” | “N=392” | “0.71 [0.12, 1.31]” | “68.1” | “0.019” |
| SDMT | “-6.44 (1.532)” | “-3.35 (0.503)” | “N=387” | “-3.09 [-6.14, -0.05]” | “-92.3” | “0.046” |
| SWRT | “-3.67 (4.134)” | “-5.20 (1.373)” | “N=387” | “1.44 [-7.45, 10.33]” | “27.7” | “0.751” |
| TMS | “8.64 (2.039)” | “5.61 (0.688)” | “N=392” | “3.02 [-1.23, 7.28]” | “-53.9” | “0.163” |
Dose response and sensitivity analyses at 36 months
Supportive endpoint at 36 months: cerebrospinal fluid neurofilament light chain
Updated 36-month analysis: cUHDRS and TFC, high dose (n=15)
Updated 36-month analysis: other secondary endpoints, high dose
| Endpoint | AMT-130 high dose (N=17), LSM change | Enroll-HD B (N=1337), LSM change | Slowing of disease progression | P-value |
|---|---|---|---|---|
| SDMT | “0.67” | “-2.78” | “Slowed HD progression by 124% based on SDMT” | “p=0.040” |
| SWRT | “1.32” | “-5.75” | “Slowed HD progression by 123% based on SWRT” | “p=0.047” |
| TMS | “1.93” | “4.77” | “Slowed HD progression by 59% based on TMS” | “p=0.114” |
Primary analysis at 48 months: cUHDRS and TFC, high dose (n=12)
Primary analysis at 48 months: other secondary endpoints, high dose
| Endpoint | AMT-130 high dose (N=12), LSM change | Enroll-HD B, LSM change | Enroll-HD B N | Slowing of disease progression | P-value |
|---|---|---|---|---|---|
| SDMT | “-2.75” | “-3.43” | “Enroll-HD B (N=634)” | “Slowed HD progression by 20% based on SDMT” | “p=0.731” |
| SWRT | “0.95” | “-7.53” | “Enroll-HD B (N=633)” | “Slowed HD progression by 113% based on SWRT” | “p=0.006” |
| TMS | “4.82” | “5.10” | “Enroll-HD B (N=631)” | “Slowed HD progression by 5.6% based on TMS” | “p=0.908” |
Post hoc analysis at 48 months against the prior Enroll-HD external control
| Endpoint | AMT-130 high dose (N=17), LSM change | Enroll-HD A (N=619), LSM change | Slowing of disease progression |
|---|---|---|---|
| cUHDRS | “-0.90” | “-1.94” | “54% slowing of disease progression at 48 months (p=0.041” |
| TFC | “-0.39” | “-1.24” | “68% slowing of disease progression at 48 months (p<0.001” |
Cerebrospinal fluid neurofilament light chain through 48 months, both doses
Interim results at 24 months against the propensity-weighted external control, July 2024
Interim results against the criteria-matched TRACK-HD cohort, December 2023
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Safety summary at the three-year data cutoff
Timing and resolution of drug-related serious adverse events
Adverse events in Cohorts 1 to 3, June 2025 data cutoff
Reclassified serious adverse event and most common adverse events, June 2025 data cutoff
Safety summary at the four-year data cutoff
Adverse events in all 51 treated participants, June 2026 data cutoff
Serious adverse events across both studies, December 2023
Study limitations
Summary
- External comparison: efficacy is assessed against a propensity score-matched external control from the Enroll-HD natural history data set. The Form 10-K states that the analyses rely on external historical controls and that these may not be accepted as a basis for regulatory approval. After a Type A meeting in January 2026, the FDA stated that it cannot agree that these data are sufficient as primary evidence of effectiveness. One commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”.
- Open-label treatment: the same commentary noted that most participants were in open-label arms, so a placebo effect is possible. An analysis of the GENERATION HD1 placebo arm found a placebo response on the cognitive scores (SDMT and SWR), which also influences the cUHDRS.
- Matching covariates: MRI data were not collected in Enroll-HD, so striatal volume, a predictor of decline and an eligibility criterion of the phase I/II studies, could not be matched. The sponsor analysis used baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR and reports that other covariates can substitute for striatal volume. A comment submitted to ICER listed limits of the natural history comparison, including bias from selection into a surgical trial versus a registry, different visit schedules, and very small numbers of treated patients at longer follow-up.
- Small numbers: 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; CSF NfL was available for 11 high-dose participants at 36 months in the three-year analysis.
- Missing data and changes in the control: missingness in the updated Enroll-HD matched controls reached 53% at 48 months, controls with longer follow-up declined more slowly, and decline in Enroll-HD B was 20% slower than in Enroll-HD A at 48 months. Against Enroll-HD B the 48-month cUHDRS result did not reach statistical significance (p=0.144); the result against Enroll-HD A comes from a post-hoc sensitivity analysis. A news report on the four-year analysis noted that the natural history database is updated, which “can alter results”.
- Analysis choices and nominal p-values: the June 2025 release described a propensity score-weighted primary analysis, while the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis. The 24-month comparison with a propensity-weighted external control of 154 participants was a post-hoc analysis. Several p-values are nominal, which the Form 10-K states regulators may weigh less than standard p-values.
- Reporting: the results are reported in company press releases, presentations, and SEC filings. One commentary noted that individual data points are not shown, error bars are not defined, data from imitation (sham) procedure participants are not shown, and there are no data on mutant HTT lowering.
Sponsor-disclosed risks of external controls, post hoc analyses, and nominal p-values
Missing data and survivor bias in the updated Enroll-HD external control
Absence of striatal volume data in Enroll-HD
Effect of volumetric criteria on 3-year decline in TRACK-HD, TRACK-ON, and PREDICT-HD
| Analysis | Volumetric criteria applied (N = 232) | Volumetric criteria not applied (N = 442) |
|---|---|---|
| cUHDRS mean change from baseline to 3 years, unweighted | “-1.4” | “-1.7” |
| cUHDRS mean change from baseline to 3 years, PS weighted | “-1.4” | “-1.4” |
| TFC mean change from baseline to 3 years, unweighted | “-1.0” | “-1.2” |
| TFC mean change from baseline to 3 years, PS weighted | “-0.9” | “-0.9” |
Independent commentary on the external control comparison, October 2025
Analyst commentary on the four-year analysis, September 2026
CT-AMT-130-01
Objective
Safety and proof of concept in a first-in-human study
Objective described in March 2022
Location and study date
United States study sites in the registry record
| Site | City |
|---|---|
| University of Alabama at Birmingham | “Birmingham” |
| University of Arizona (Surgical Site Only) | “Tucson” |
| University of California, San Francisco | “San Francisco” |
| CenExel Rocky Mountain Clinical Research | “Englewood” |
| Rush University Medical Center | “Chicago” |
| Johns Hopkins University | “Baltimore” |
| University of Michigan Department of Neurology | “Ann Arbor” |
| Ohio State University | “Columbus” |
| Vanderbilt University Medical Center | “Nashville” |
| The University of Texas | “Houston” |
| Virginia Commonwealth University VCU School of Medicine, Department of Neurology | “Richmond” |
| University of Washington Medical Center | “Seattle” |
Study dates in the registry record
| Date | Registry value |
|---|---|
| Study start (actual) | “2019-09-06” |
| Primary completion (estimated) | “2029-06” |
| Study completion (estimated) | “2029-12” |
| Last update posted | “2025-10-21” |
First participants treated in the United States, June 2020
Study dates in the original registry record, October 2019, superseded
| Field | Registry value |
|---|---|
| Version | “Viewing V1 (2019-10-07)” |
| Study start | “2019-10 [Estimated]” |
| Primary completion | “2022-12 [Estimated]” |
| Study completion | “2026-05 [Estimated]” |
Study design
Design in the current registry record
Design fields in the current registry record
| Field | Registry value |
|---|---|
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential” |
| Masking | “None (Open Label)” |
Randomized, quadruple-masked parallel design with an 18-month core period: registry version 1, October 2019, superseded
Randomized, triple-masked sequential design with crossover: registry version 33, October 2024, superseded
| Field | Registry value |
|---|---|
| Version | “Viewing V33 (2024-10-22)” |
| Interventional study model | “Sequential Assignment” |
| Masking | “Triple (Participant, Investigator, Outcomes Assessor)” |
| Allocation | “Randomized” |
| Enrollment | “37 [Estimated]” |
Blinded core period of 18 months at first dosing, June 2020, superseded
Blinded 12-month core period followed by five years of follow-up, March 2022
Cohort 3 as first planned: alternative stereotactic navigation, December 2021, superseded in June 2023
Cohort 3 redesigned to study perioperative immunosuppression, June 2023
Cohort 3: blinded randomization to high or low dose
Cohort 4: high dose in participants with lower striatal volumes
Eligibility criteria
Inclusion criteria in the current registry record
Striatal volume criteria: minimum volumes in Cohorts 1 to 3 and lower volumes in Cohort 4
Selected exclusion criteria in the current registry record
Eligibility in the original registry record, October 2019, superseded
Treatment
Doses and route in the current registry record
Imitation (sham) surgery in Cohorts 1 and 2
Imitation surgery with partial-thickness burr holes: registry version 1, October 2019, superseded
Cohort 4: high dose with perioperative dexamethasone
Study outcomes
Rationale for using adverse events as the primary endpoint
Primary outcome: number and type of adverse events at 12 months
First-in-human trial with staged dosing reviewed by the Data Safety Monitoring Board
Secondary outcome: persistence of AMT-130 in the brain
Exploratory outcomes in the current registry record
| Exploratory outcome | Registry entry |
|---|---|
| Cerebrospinal fluid mutant huntingtin | “CSF Mutant Protein (fM)” |
| Neurofilament light chain | “CSF/Serum Neurofilament Light Chain (pg/mL)” |
| Rating scale | “Unified Huntington Disease Rating Scale (UHDRS)” |
| Quantitative motor testing | “Quantitative Motor (Q-Motor) Testing” |
| Imaging | “Magnetic Resonance Imaging (MRI)” |
| Health-related quality of life | “Neuro-QoL Measures” |
Additional exploratory outcomes in registry version 1, October 2019
Limitation of cerebrospinal fluid mutant huntingtin as a measure of brain levels
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at first dosing, June 2020, superseded
Participants in Cohorts 1 and 2 by arm
Planned size of Cohort 3, December 2023
Estimated total enrollment in the current registry record
| Field | Registry value |
|---|---|
| Enrollment (estimated) | “43” |
Description of analysis sets
Participants evaluable for biomarkers in the low-dose cohort, June 2022
Comparators and exclusion of crossover participants in the June 2023 interim analysis
Results
Participant disposition
Enrollment of Cohorts 1 and 2 completed, March 2022
Crossover of control participants, 2022 to 2023
Cohort 3 enrollment completed, February 2025
Cohort 4 recruited in October 2025 and dosed in the fourth quarter of 2025
Baseline characteristics
First four participants in the low-dose cohort, December 2021
Low-dose cohort of 10 participants, June 2022
Cohort 4 baseline characteristics
| Characteristic (mean or %) | AMT-130 high-dose Cohort 4 (n=6) |
|---|---|
| Sex, males (%) | “16.7” |
| Age | “43.7” |
| CAG repeats | “44.5” |
| DCL = 3, 4 (%) | “16.7, 83.3” |
| TFC | “12.0” |
Efficacy results
First four participants at one year, December 2021
Low-dose cohort at 12 months: cerebrospinal fluid mutant huntingtin, June 2022
Low-dose cohort at 12 months: cerebrospinal fluid neurofilament light chain, June 2022
U.S. interim analysis: clinical measures against baseline, controls, and a TRACK-HD natural history cohort, June 2023
U.S. interim analysis: biomarkers and brain volume, June 2023
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
First four participants at one year, December 2021
Low-dose cohort at 12 months: deep vein thrombosis and postoperative delirium, June 2022
High-dose procedures paused after suspected unexpected serious adverse reactions, August 2022
High-dose treatment resumed with additional monitoring, October 2022
U.S. interim analysis: serious adverse events and suspected unexpected serious adverse reactions, June 2023
Cohort 3: serious adverse events related to immunosuppression
Cohort 4: treatment-related central nervous system inflammation
Study limitations
Summary
- Changed blinding and registry inconsistencies: the current ClinicalTrials.gov record lists allocation as non-randomized and masking as none (open label), while its official title describes a randomized, double-blind, sham control and open-label study. Version 1 (2019) listed a randomized, quadruple-masked design with an estimated enrollment of 26 and a blinded 18-month core period; version 33 (2024) listed a randomized, triple-masked design with an estimated enrollment of 37 and a blinded 12-month core period; the current record lists an estimated enrollment of 43. Cohort 4 is open-label.
- Short randomized comparison: the sham comparison in Cohorts 1 and 2 covered the blinded 12-month period, after which sham participants could cross over. Four of the six control participants in the high-dose cohort crossed over and the other two did not meet the inclusion criteria, and interim analyses compared treated participants with control participants only up to 12 months and excluded efficacy data from crossover participants.
- Small numbers: Cohorts 1 and 2 randomized 26 participants (six low dose, 10 high dose, 10 sham); Cohort 3 enrolled 12 and Cohort 4 six.
- Safety as the primary outcome: the study is designed to establish safety and proof-of-concept, and the registered primary outcome is adverse events at 12 months.
- Target engagement: the company states that CSF mutant huntingtin is not believed to be materially representative of mutant huntingtin in the targeted brain regions, and one commentary noted that there are no data on mutant HTT lowering.
- Protocol changes: version 1 required ≥44 CAG repeats and an imitation surgery with bilateral partial thickness burr holes; the current record requires ≥40 CAG repeats and a simulated procedure with skin incisions only and no burr holes. Cohort 3 was first planned to study alternative stereotactic navigation systems and was redesigned to study perioperative immunosuppression.
CT-AMT-130-02
Objective
Primary and secondary objectives in the EU Clinical Trials Register
Expanding exposure to both doses after the U.S. study
Dose selection for later development, March 2022
Location and study date
Sites in Poland, the United Kingdom, and Germany at first dosing, February 2022
Study sites and dates in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Site, Warsaw, Poland | “Instytut Psychiatrii i Neurologii” |
| Site, Warsaw, Poland | “Interventional Neuro Center” |
| Site, Cardiff, United Kingdom | “Cardiff University” |
| Site, London, United Kingdom | “National Hospital for Neurology & Neurosurgery” |
| Study start (actual) | “2021-10-07” |
| Primary completion (estimated) | “2029-03” |
| Study completion (estimated) | “2029-10-07” |
EU trial record after transition to the Clinical Trials Regulation
| Field | Record value |
|---|---|
| Protocol code | “CT-AMT-130-02” |
| Transition trial | “Yes” |
| Locations | “Poland” |
| Start of trial | “Start of trial 07/10/2021” |
| Current status in Poland | “Ongoing, recruitment ended” |
| Recruitment end in Poland | “15/10/2024” |
| Estimated global end date | “31/12/2029” |
Study design
Open-label Cohorts 1 and 2 and randomized Cohort 3 in the current registry record
Design fields in the current registry record
Non-randomized, open-label ascending-dose design: registry version 1, February 2022, superseded
Six-month post-treatment period followed by five years of follow-up
Eligibility criteria
Inclusion criteria in the EU Clinical Trials Register
Genetic and striatal volume criteria in the current registry record
Exclusion criteria: suicide attempt within 1 year
Same early manifest criteria as the U.S. study
Treatment
Doses by cohort in the current registry record
Investigational product concentration in the EU Clinical Trials Register
| Field | Register value |
|---|---|
| Concentration number | “2 x 10e13 gc/mL” |
All participants dosed with AMT-130
Study outcomes
Rationale for using safety measures as the primary endpoint
Integrated two-study program with staggered enrollment under one safety board
Primary outcomes at 6 months in the ClinicalTrials.gov record
Primary end points in the EU Clinical Trials Register
Secondary end points: vector DNA and miRNA expression in cerebrospinal fluid
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of 15 participants in two open-label cohorts, February 2022
Actual enrollment in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Enrollment (actual) | “14” |
Description of analysis sets
No evidence found.
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Suspected unexpected serious adverse reactions in two high-dose participants at one site, July 2022
Plan to resume dosing in the European study, November 2022
Safety notifications in the EU trial record
| Notification | Record value |
|---|---|
| Serious breach | “Serious Breach (0)” |
| Unexpected event | “Unexpected Event (0)” |
| Urgent safety measure | “Urgent Safety Measure (0)” |
| Temporary halt | “Temporary Halt (0)” |
Study limitations
Summary
- Open-label, uncontrolled design with inconsistent records: the EU Clinical Trials Register lists the trial as not controlled, not randomised, open, and not double blind. The ClinicalTrials.gov record describes open-label Cohorts 1 and 2 and randomization in Cohort 3 only, lists allocation as randomized and masking as none (open label), and gives an official title describing a randomized, double-blind study; version 1 (2022) listed a non-randomized, open-label design with an estimated enrollment of 15.
- Enrollment: 15 participants were planned (six low dose, nine high dose). The Form 10-K reports 13 participants enrolled and treated (six low dose, seven high dose), while the ClinicalTrials.gov record lists an actual enrollment of 14.
- Sites: the February 2022 release named sites in Poland, the United Kingdom, and Germany; the ClinicalTrials.gov record lists sites in Poland and the United Kingdom, and the CTIS record lists Poland.
- Results reporting: the pooled-analysis protocols pool data across the U.S. and EU studies, and the registered primary outcomes are safety and tolerability measures, including adverse events.
- Safety: suspected unexpected severe adverse reactions occurred in two high-dose participants treated at a single clinical site.
Planned confirmatory trial
Objective
No evidence found.
Location and study date
Screening to begin in the United States by the end of 2026
Study design
Randomized, standard-of-care-controlled design, November 2026
Standard-of-care control considered after the June 2026 Type B meeting, July 2026
Sham surgery-controlled study recommended after the January 2026 Type A meeting, superseded in June 2026
Eligibility criteria
No evidence found.
Treatment
Ifezuntirgene inilparvovec or standard of care, randomized 2:1
Study outcomes
Rationale for using total functional capacity as the primary endpoint
Total Functional Capacity in the phase I/II data at 48 months
Rate of decline by baseline Total Functional Capacity
“The annual rate of decline for 575 patients with baseline TFC scores of 7 to 13 was 0.97 (SE 0.06), was 0.38 (SE 0.08) for 270 patients with baseline TFC scores of 3 to 6, and was 0.06 (SE 0.1) for 101 patients with TFC scores of 0 to 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These rates of functional decline and the covariates that modify them should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Absence of placebo response on Total Functional Capacity: GENERATION HD1 placebo arm
Functional ability as a regulatory outcome and ceiling effects in early disease
“The assessment of functional ability as a clinical outcome is deemed essential for therapeutic approval by regulatory agencies such as the FDA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, these scales have limiting ceiling effects that make them unattractive for use in earlier stages of HD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Total Functional Capacity at 65 weeks as the main measure of effectiveness in the Nurzigma application
Internal consistency of the UHDRS domains, including functional capacity
“The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We found there was a high degree of internal consistency within each of the domains of the UHDRS and that there were significant intercorrelations between the domains of the UHDRS, with the exception of the total behavioral score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Approximately 200 participants planned
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- Planned design only: the trial is described in company releases and the Form 10-Q as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint, and screening is planned to begin in the United States by the end of 2026.
- Control without a sham procedure: after a Type A meeting in January 2026 the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; in 2026 it later sought alignment on a confirmatory design that included consideration of a randomized standard-of-care control instead of a sham procedure.
- Primary endpoint: the UHDRS TFC appears to have a ceiling effect in early stage Huntington's disease, and it lacks core clinimetric data on test-retest reliability and internal consistency.
- Timing: the FDA stated that the confirmatory study should be well underway, and potentially fully enrolled, at the time of accelerated approval; the company expects the study to be well underway by the time of potential approval.